药店国别：
产地国家：美国
处 方 药：
所属类别：50毫升/瓶
包装规格：50毫升/瓶
计价单位：瓶
生产厂家中文参考译名:基立福
生产厂家英文名:Grifols
塬产地英文商品名:HUMAN ALBUMIN GRIFOLS 25% 50MLS/VIAL
塬产地英文药品名:ALBUMIN HUMAN
中文参考商品译名:基立福25%人血白蛋白 50毫升/瓶
中文参考药品译名:人血白蛋白
简介：部分中文人血白蛋白处方资料(仅供参考) 【
药品名称】
品 名：基立福人血白蛋白
汉语拼音：Human ALBumin Grifols 25% 50ml 【
性状】 本品为略粘稠、黄色或绿色至棕色澄明液体。 【
药理作用】 1.增加血容量和维持血浆胶体渗透压：白蛋白佔血浆胶体渗透压的80%，主要调节组织与血管之间水分的动态平衡。由于白蛋白分子量较高，与盐类及水分相比，透过膜内速度较慢，使白蛋白的胶体渗透压与毛细管的静力压抗衡，以此维持正常与恒定的血容量;同时在血迴圈中，1g白蛋白可保留18ml水，每5g白蛋白保留迴圈内水分的能力约相当于100ml血浆或200ml全血的功能，从而起到增加迴圈血容量和维持血浆胶体渗透压的作用。 2.运输及解毒：白蛋白能结合阴离子也能结合阳离子，可以输送不同的物质，也可以将有毒物质输送到解毒器官。 3.营养供给:组织蛋白和血浆蛋白可互相转化，在氮代谢障碍时，白蛋白可作为氮源为组织提供营养。 【
适应症】 1.失血创伤、烧伤引起的休克。 2.脑水肿及损伤引起的颅压升高。 3.肝硬化及肾病引起的水肿或腹水。 4.低蛋白血症的防治。 5.新生儿高胆红素血症。 6.用于心肺分流术、烧伤的辅助治疗、血液透析的辅助治疗和成人唿吸窘迫综合徵。 【
用法用量】 用法：一般採用静脉滴注或静脉推注。为防止大量注射时机体组织脱水，可採用5%葡萄糖注射液或氯化钠注射液适当稀释作静脉滴注(宜用备有滤网装置的输血器)。滴注速度应以每分鐘不超过2ml为宜，但在开始15分鐘内，应特别注意速度缓慢，逐渐加速至上述速度。 用量：使用剂量由医师酌情考虑，一般因严重烧伤或失血等所致休克，可直接注射本品5～10g，隔4～6小时重復注射1次。在治疗肾病及肝硬化等慢性白蛋白缺乏症时，可每日注射本品5～10g，直至水肿消失，血清白蛋白含量恢復正常为止。 【
不良反应】 使用本品一般不会产生不良反应，偶可齣现寒颤、发热、颜面潮红、皮疹、噁心呕吐等症状，快速输注可引起血管超负荷导致肺水肿，偶有过敏反应。 【
禁忌】 1.对白蛋白有严重过敏者。 2.高血压患者，急性心臟病者、正常血容量及高血容量的心力衰竭患者。 3.严重贫血患者。 4.肾功能不全者。 【
注意事项】 1.药液呈现混浊、沉淀、异物或瓶子有裂纹、瓶盖鬆动、过期失效等情况不可使用。 2.本品开启后，应一次输注完毕，不得分次或给第二人输用。 3.输注过程中如发现病人有不适反应，应立即停止输用。 4.有明显脱水者应同时补液。 5.运输及贮存过程中严禁冻结。 【
孕妇及哺乳期妇女用药】 对孕妇或可能怀孕妇女的用药应慎重，如有必要应用时，应在医师指导和严密观察下使用。 【
药物相互作用】本品不宜与血管收缩药，蛋白水解 或含酒精溶剂的注射液混合使用。 【
药物过量】因本品有高渗作用，过量注射时，可造成脱水、机体迴圈负荷增加、充血性心力衰竭和肺水肿。 【
规格】25%/50ml 【
贮藏】2～8℃，避光保存
Human Albumin Grifols 25% Albumin (Human) U.S.P. Description Albumin (Human)， Human Albumin Grifols® 25% is a sterile aqueous solution for single dose intravenous administration containing 25% human albumin (weight/volume). Human Albumin Grifols® 25% is prepared by a cold alcohol fractionation method from pooled human plasma obtained from venous blood. The product is stabilized with 0.08 millimole sodium caprylate and 0.08 millimole sodium acetyltryptophanate per gram of protein. Human Albumin Grifols® 25% is osmotically equivalent to five times its volume of normal citrated plasma. A liter of Human Albumin Grifols 25% solution contains 130-160 milliequivalents of sodium ion. The product contains no preservatives. Human Albumin Grifols® 25% is heated at 60 °C for ten hours. No positive assertion can be made， however， that this heat treatment completely destroys the causative agents of viral hepatitis. There are no known cases of viral hepatitis which have resulted from the administration of Human Albumin Grifols® 25%. Clinical Pharmacology Albumin is a highly soluble， globular protein (MW 66，500)， accounting for 70-80% of the colloid osmotic pressure of plasma. Therefore， it is important in regulating the osmotic pressure of plasma1，2. Human Albumin Grifols® 25% supplies the oncotic equivalent of approximately 5 times its volume of human plasma. It will increase the circulating plasma volume by an amount approximately 3.5 times the volume infused within 15 minutes， if the recipient is adequately hydrated3. This extra fluid reduces hemoconcentration and decreases blood viscosity. The degree and duration of volume expansion depend upon the initial blood volume. When treating patients with diminished blood volume， the effect of infused albumin may persist for many hours. The hemodilution lasts for a shorter time when albumin is administered to individuals with normal blood volume. Albumin is also a transport protein and binds naturally occurring， therapeutic， and toxic materials in the circulation2. Albumin is distributed throughout the extracellular water and more than 60% of the body albumin pool is located in the extravascular fluid compartment. The total body albumin in a 70 kg man is approximately 320 g; it has a circulating life span of 15-20 days， with a turnover of approximately 15 g per day.1Indications and Usage Albumin (Human)， Human Albumin Grifols® 25% is indicated: a. For the prevention and treatment of hypovolemic shock2，4， and b. in conjunction with exchange transfusion in the treatment of neo-natal hyperbilirubinemia.2 c. Concentrated Albumin (Human) solutions (e.g.， 25%) have also been used successfully to induce diuresis in some patients with acute nephrosis1 who were refractory to other forms of treatment. However， Albumin (Human) has no role in the management of chronic nephrosis. d. More dilute Albumin (Human) solutions (e.g.， 5%) have been used as pump priming fluids during cardiopulmonary bypass. However， an adequate blood volume can also be maintained during bypass with crystalloid as the only priming fluid without a significant difference in the clinical outcome achieved.1，2 Conditions in which Albumin (Human) use is usually not justified: a. Postoperative hypoproteinemia. Major surgery or other injury of capillary walls may lead to substantial losses of circulating albumin over and above those due to bleeding.1，2，4，5 However， this redistribution of albumin in the body rarely causes clinically significant hypovolemia， hence treatment with Albumin (Human) is usually not indicated. b. Renal dialysis. Patients undergoing long-term hemodialysis may occasionally require Albumin (Human) for the treatment of an acute volume or oncotic deficit1. Such patients who receive Albumin(Human) should be carefully monitored for signs of circulatory overload， to which they are particularly sensitive. c. Paracentesis or Acute liver failure. Removal of even large volumes of ascites fluid is usually well tolerated. However， if significant hypovolemia and/or cardiovascular function changes ensue， Albumin (Human) can provide short-term benefit. Similarly， in patients with acute liver failure， Albumin may have a stabilizing effect， but the therapy must be guided by individual circumstances.1 Albumin (Human) is of no value in the management of chronic cirrhosis. Unless the pathologic condition responsible for hypoalbuminemia can be corrected， administration of Albumin (Human) can afford only symptomatic relief. There is NO valid reason for the use of Albumin(Human) as an intravenous nutrient. Warnings Solutions of Albumin (Human)， Human Albumin Grifols® 25% should not be used if they appear turbid or if there is sediment in the bottle. Do not begin administration more than 4 hours after the container has been entered. Discard unused portion. Human Albumin Grifols® 25% is made from human plasma. Products made from human plasma may contain infectious agents， such as viruses， that can cause disease. The risk that such products will transmit an infectious agent has been reduced by screening plasma donors for prior exposure to certain viruses， by testing for the presence of certain current virus infections， and by inactivating certain viruses by pasteurization. Despite these measures， such products can still potentially transmit disease. A theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD) also is considered extremely remote. No cases of transmission of viral diseases or CJD have ever been identified for albumin. There is also the possibility that unknown infectious agents may be present in such products. ALL infections thought by a physician possibly to have been transmitted by this product should be reported by the physician or other healthcare provider to Grifols USA， at 703-860-5057. The physician should discuss the risks and benefits of this product with the patient. There exists a risk of potentially fatal hemolysis and acute renal failure from the inappropriate use of Sterile Water for Injection as a diluent for Albumin (Human) 25%. Acceptable diluents include 0.9% Sodium Chloride or 5% Dextrose in Water. Precautions Human Albumin Grifols® 25% should be administered with caution to patients with low cardiac reserve. Rapid infusion may cause vascular overload with resultant pulmonary edema. Patients should be closely monitored for signs of increased venous pressure. A rapid rise in blood pressure following infusion necessitates careful observation of injured or postoperative patients to detect and treat severed blood vessels that may have bled at a lower pressure. Patients with marked dehydration require administration of additional fluids. Human Albumin Grifols® 25% may be administered with the usual dextrose and saline intravenous solutions. However， certain solutions containing protein hydrolysates or alcohol must not be infused through the same administration set in conjunction with Human Albumin Grifols® 25% since these combinations may cause the proteins to precipitate. Pregnancy category C. Animal reproduction studies have not been conducted with Albumin (Human). It is also not known whether Albumin (Human) can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Albumin (Human) should be given to a pregnant woman only if clearly needed. Adverse Reactions Allergic or pyrogenic reactions are characterized primarily by fever and chills; urticaria， rash， nausea， vomiting， tachycardia， headache and hypotension have also been reported. Should an adverse reaction occur， slow or stop the infusion for a short period of time which may result in the disappearance of the symptoms. If administration has been stopped and the patient requires additional Human Albumin Grifols 25%， material from a different lot should be used. Human Albumin Grifols® 25% particularly if administered rapidly， may result in vascular overload with resultant pulmonary edema. Dosage and Administration Albumin (Human)， Human Albumin Grifols 25% is administered intravenously. The total dosage will vary with the individualIn adults， an initial infusion of 100 mL is suggested. Additional amounts may be administered as clinically indicated. The initial dosage in children will vary with the clinical state and body weight. A dose one-quarter to onehalf the adult dose may be administered， or dosage may be calculated on the basis of 1-3 mL per kg of body weight. For infants suffering from hemolytic disease of the newborn the appropriate dose for binding of free serum bilirubin is 1 gram per kilogram of body weight. This may be administered before or during the exchange procedure6. In the treatment of the patient in shock with greatly reduced blood volume， Human Albumin Grifols® 25% may be administered as rapidly as necessary in order to improve the clinical condition and restore normal blood volume. This may be repeated in 15-30 minutes if the initial dose fails to prove adequate. In the patient with a slightly low or normal blood volume， the rate of administration should be 1 mL per minute. The usual rate of administration in children should be one-quarter the adult rate. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration， whenever solution container permit. Directions for Use (When Administration Set is Used)Flip off plastic cap on top of the vial and expose rubber stopper. Cleanse exposed rubber stopper with a suitable germicidal solution， being sure to remove any excess. Observe aseptic technique and prepare sterile intravenous equipment as follows:Close clamp on administration set (delivers approximately 19 drops/mL). With bottle upright， thrust piercing pin straight through stopper center. Do not twist or angle. Immediately invert bottle to automatically establish proper fluid level in drip chamber (half full). Attach infusion set to administration set， open clamp and allow solution to expel air from tubing and needle， then close clamp. Make venipuncture and adjust flow. Discard all administration equipment after use. Discard any unused contents. Directions for Use (When Administration Set is Not Used)Flip off plastic cap on top of the vial and expose rubber stopper. Cleanse exposed rubber stopper with a suitable germicidal solution， being sure to remove any excess. Observe aseptic technique and prepare sterile intravenous equipment as follows:Using aseptic technique， attach filter needle to a sterile disposable plastic syringe. Insert filter needle into Albumin (Human)， Human Albumin Grifols 25% vial. Aspirate Human Albumin Grifols® 25% from the vial into the syringe. Remove and discard the filter needle from the syringe. Attach desired size needle to syringe. Discard all administration equipment after use. Discard any unused contents. How Supplied 50 mL vial Human Albumin Grifols® 25% 100 mL vial Human Albumin Grifols® 25% Storage Human Albumin Grifols® 25% is stable for three years providing storage temperature does not exceed 30 °C. Protect from freezing. CautionFederal (USA) law prohibits dispensing without a prescription.